[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Arizona, 2022 - Google Patents

ACNP 61 st Annual Meeting: Poster Abstracts P541-P809

Arizona, 2022

View HTML
Document ID
3006301657196364698
Author
Arizona P
Publication year

External Links

Snippet

Background: The human dopamine synthesis capacity can be analyzed in vivo using 18F- FDOPA PET. This tracer kinetic model is known to be complex due to the presence of multiple compartments, as well as prominent metabolites that also enter the brain. Several …
Continue reading at www.nature.com (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00

Similar Documents

Publication Publication Date Title
Manchia et al. Serotonin dysfunction, aggressive behavior, and mental illness: exploring the link using a dimensional approach
Maletic et al. Integrated neurobiology of bipolar disorder
Yu et al. Cognitive and neural correlates of depression-like behaviour in socially defeated mice: an animal model of depression with cognitive dysfunction
Krystal et al. γ-aminobutyric acid type A receptors and alcoholism: intoxication, dependence, vulnerability, and treatment
Bailey et al. Recent progress in understanding the pathophysiology of post-traumatic stress disorder: implications for targeted pharmacological treatment
Sinclair et al. GABA-B agonist baclofen normalizes auditory-evoked neural oscillations and behavioral deficits in the Fmr1 knockout mouse model of fragile X syndrome
Cao et al. TMS-EEG: An emerging tool to study the neurophysiologic biomarkers of psychiatric disorders
Dandekar et al. Increased dopamine receptor expression and anti-depressant response following deep brain stimulation of the medial forebrain bundle
Moore et al. Neuropharmacology of compulsive eating
Schilman et al. The role of the striatum in compulsive behavior in intact and orbitofrontal-cortex-lesioned rats: possible involvement of the serotonergic system
Winter et al. Altered serotonergic and GABAergic neurotransmission in a mice model of obsessive-compulsive disorder
Aguilar et al. THC and endocannabinoids differentially regulate neuronal activity in the prefrontal cortex and hippocampus in the subchronic PCP model of schizophrenia
Sandhu et al. Phasic stimulation of midbrain dopamine neuron activity reduces salt consumption
Lladó-Pelfort et al. Effects of hallucinogens on neuronal activity
Wong et al. The putative role of the relaxin-3/RXFP3 system in clinical depression and anxiety: A systematic literature review
Stefan et al. Onset of action of levetiracetam: a RCT trial using therapeutic intensive seizure analysis (TISA)
Zhong et al. (2R, 6R)-hydroxynorketamine alleviates electroconvulsive shock-induced learning impairment by inhibiting autophagy
Arizona ACNP 61 st Annual Meeting: Poster Abstracts P541-P809
Simoes Fernandes et al. Precision psychiatry with immunological and cognitive biomarkers: a multi-domain prediction for the diagnosis of bipolar disorder or schizophrenia using machine learning
Broussard Immune Treatments for Alcohol Use Disorder: Translational Literature Review and Exploration of Clinical Mechanisms
Sedhom et al. Potential Link Between Exercise and N-Methyl-D-Aspartate Glutamate Receptors in Alcohol Use Disorder: Implications for Therapeutic Strategies
Hahn et al. ACNP 60 th Annual Meeting: Poster Abstracts P551–P830
Friend et al. ACNP 57th Annual Meeting: Poster Session II
Peuskens et al. Sara Kollack-Walkerl, Ilya Lipkovichl, Walter Deberdtl, Peter F. Buckleyz, John G. Csernanskya, Josef
Bigio et al. ACNP 57th Annual Meeting: Poster Session I